Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -763.39% is 20% above its 4-year average of -951.37%, near the high end of its 4-year range (-5381.79%–876.76%).
24.79% above its 12-month average of -1015.01%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1077.59%.
EBITDA MARGIN
-763.39%
EBITDA MARGIN AVG TTM
-1015.01%
EBITDA MARGIN AVG 3Y
-1110.73%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+24.79%
CURRENT VS 3Y AVG
+31.27%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
60 Degrees Pharmaceuticals, Inc.
Market Cap
$3.90M
EBITDA Margin
-763.39%
TTM Avg
-1015.01%
3Y Avg
-1110.73%
5Y Avg
N/A
Market Cap
$3.97M
EBITDA Margin
-890.82%
TTM Avg
-527.81%
3Y Avg
-554.45%
5Y Avg
-445.87%
Market Cap
$3.69M
EBITDA Margin
-2411.68%
TTM Avg
-15920.55%
3Y Avg
-15920.55%
5Y Avg
-10610.40%
Market Cap
$3.66M
EBITDA Margin
-334.54%
TTM Avg
-323.48%
3Y Avg
-700.81%
5Y Avg
-1335.84%
Market Cap
$4.11M
EBITDA Margin
-38402.78%
TTM Avg
-17909.83%
3Y Avg
-9620.57%
5Y Avg
-7243.11%
Market Cap
$3.64M
EBITDA Margin
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$3.63M
EBITDA Margin
-16.02%
TTM Avg
-16.02%
3Y Avg
-6.88%
5Y Avg
6.20%
Market Cap
$4.18M
EBITDA Margin
-1456.00%
TTM Avg
-1456.00%
3Y Avg
-1456.00%
5Y Avg
-1456.00%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 60 Degrees Pharmaceuticals, Inc. (SXTP) | $3.90M | -763.39% | -1015.01% | -1110.73% | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.97M | -890.82% | -527.81% | -554.45% | -445.87% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $3.69M | -2411.68% | -15920.55% | -15920.55% | -10610.40% |
| Evogene Ltd. (EVGN)vs › | $3.66M | -334.54% | -323.48% | -700.81% | -1335.84% |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.11M | -38402.78% | -17909.83% | -9620.57% | -7243.11% |
| Cadrenal Therapeutics, Inc. Common Stock (CVKD)vs › | $3.64M | N/A | N/A | N/A | N/A |
| WORK Medical Technology Group Ltd. Class A (WOK)vs › | $3.63M | -16.02% | -16.02% | -6.88% | 6.20% |
| Eocene Ltd. (EOCN)vs › | $3.64M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.18M | -1456.00% | -1456.00% | -1456.00% | -1456.00% |
| Nexalin Technology, Inc. (NXL)vs › | $3.49M | -2774.55% | -3680.87% | -3159.91% | -3026.36% |
Gross Margin
19.4%
EBITDA Margin
-763.4%
Operating Margin
-774.9%
Net Margin
-730.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1077.59% |
| 2026-03-31 | -1276.49% |
| 2025-12-31 | -624.22% |
| 2025-09-30 | -526.21% |
| 2025-06-30 | -1570.51% |
| 2025-03-31 | -1158.09% |
| 2024-12-31 | -787.90% |
| 2024-09-30 | -1555.17% |
| 2024-06-30 | -3342.94% |
| 2024-03-31 | -1249.42% |
| 2023-12-31 | -4380.35% |
| 2023-09-30 | -2923.20% |
| 2023-06-30 | -1281.67% |
| 2023-03-31 | -5381.79% |
| 2022-12-31 | 876.76% |
| 2022-09-30 | -116.35% |
| 2022-06-30 | -1478.30% |
| 2022-03-31 | -308.13% |
| 2021-12-31 | -165.35% |
